{
    "clinical_study": {
        "@rank": "85720", 
        "arm_group": {
            "arm_group_label": "OZURDEX\u00ae", 
            "description": "Patients who receive dexamethasone 700 \u338d (OZURDEX\u00ae) intravitreal implant treatment for Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion as per local standard of care in clinical practice."
        }, 
        "brief_summary": {
            "textblock": "This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy\n      of dexamethasone 700 \u338d (OZURDEX\u00ae)  intravitreal implant used to treat Branch Retinal Vein\n      Occlusion or Central Retinal Vein Occlusion in clinical practice."
        }, 
        "brief_title": "Safety and Efficacy of Dexamethasone (OZURDEX\u00ae) Intravitreal Implant in Korea", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Retinal Vein Occlusion", 
        "condition_browse": {
            "mesh_term": "Retinal Vein Occlusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion treated\n             with (OZURDEX\u00ae) in clinical practice.\n\n        Exclusion Criteria:\n\n          -  Patients with eye infections\n\n          -  Patients with glaucoma."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion treated with\n        (OZURDEX\u00ae) in clinical practice."
            }
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01976650", 
            "org_study_id": "206207-029"
        }, 
        "intervention": {
            "arm_group_label": "OZURDEX\u00ae", 
            "description": "dexamethasone 700 \u338d (OZURDEX\u00ae) intravitreal implant  treatment for Branch Retinal Vein Occlusion or Central Retinal Vein Occlusion as per local standard of care in clinical practice.", 
            "intervention_name": "dexamethasone 700 \u338d intravitreal implant", 
            "intervention_type": "Drug", 
            "other_name": "OZURDEX\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Dexamethasone acetate", 
                "Dexamethasone", 
                "Dexamethasone 21-phosphate", 
                "BB 1101"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 30, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "overall_contact": {
            "email": "clinicaltrials@allergan.com", 
            "last_name": "Allergan Inc."
        }, 
        "overall_official": {
            "affiliation": "Allergan", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of Participants with Adverse Events or Adverse Drug Reactions", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }, 
            {
                "measure": "Best Corrected Visual Acuity", 
                "safety_issue": "No", 
                "time_frame": "4 Years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01976650"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Allergan", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Allergan", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}